Selecta Biosciences
480 Arsenal Way
Building One
Watertown
Massachusetts
02472
United States
Tel: 617-923-1400
Fax: 617-924-3454
Website: http://www.selectabio.com/
Email: info@selectabio.com
About Selecta Biosciences
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVPTM) with a range of biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company's lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's SEL-403 product candidate, a combination therapy consisting of SVP-Rapamycin and LMB-100, recently entered a Phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. Selecta's proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP also holds potential in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.
Stock Symbol: SELB
Exchange: NASDAQ
113 articles with Selecta Biosciences
-
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
6/16/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Raymond James Human Health Innovation Conference
-
Selecta Biosciences to Participate at the LifeSci Partners Genetic Medicines Summit 2021
6/14/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update at the LifeSci Partners Genetic Medicines Summit 2021
-
Selecta Biosciences to Participate at the Jefferies Virtual Healthcare Conference - May 25, 2021
5/25/2021
Selecta Biosciences, Inc., a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021.
-
Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
5/13/2021
Selecta Biosciences today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update
5/6/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, May 13, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2021
-
Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
4/29/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually from May 11-14, 2021.
-
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
4/29/2021
– Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains on track –
-
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
4/5/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021.
-
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
3/11/2021
- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - - Methylmalonic acidemia (MMA) gene therapy program in collaboration with -
-
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
3/4/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, March 11, 2020, at 8:30 a.m.
-
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
3/1/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.
-
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
2/24/2021
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the peer-reviewed publication of a study investigating the effects of the co-administration of ImmTOR nanoparticles to adeno-associated viral (AAV) vectors on transgene expression in mice
-
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
2/17/2021
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –
-
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/16/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10 th
-
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
1/6/2021
Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced preclinical data that validate the ImmTOR platform’s potential to enhance the efficacy, safety and durability of adeno-associated viral (AAV) vector gene therapies.
-
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
1/4/2021
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.
-
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA
11/19/2020
Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations.
-
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy MMA-101
11/19/2020
Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease de
-
Selecta Biosciences to Participate in Upcoming Investor Conferences - Nov 10, 2020
11/10/2020
Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:
-
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
11/5/2020
Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022 IND filing for gene therapy expected in Q1 2021; preliminary Phase 1 data expected by end of 2021 IgA nephropathy program underway with IND expected by end of 2021 Ended quarter with cash position of $147.6 million with runway into the first quarter of 2023 Company to host conference call today at 8:30 a.m. ET